Following Eli Lilly and Johnson & Johnson, Sanofi is aiming to change how it participates in the 340B program, a federal drug pricing program created in 1992, The Wall Street Journal reported Nov. 22.

When the 340B drug pricing program was established in 1992, Congress intended for the program to help low-income and uninsured patients with their prescription drugs. The pharmaceutical companies ...

Republican lawmakers in the House have introduced a bill Tuesday that tightens eligibility and public reporting requirements within the 340B Drug Discount Program, earning the applause of industry ...

As federal scrutiny and legislative proposals continue around the 340B drug pricing program, health systems are stepping up advocacy efforts and preparing for potential disruptions. At St. Louis-based ...

The 340B program, which was created more than 30 years ago, allows healthcare providers that serve large populations of low-income patients to buy outpatient drugs at a significantly discounted rate.

The 340B drug discount program incentivizes hospitals to purchase outpatient clinics and prescribe more and higher-cost drugs — behaviors that tend to increase costs for the federal government and ...

The rapid expansion of the federal 340B drug pricing program is significantly affecting Medicaid budgets, particularly in states where managed care plans oversee prescription drug benefits. New ...

A federal court has rejected a lawsuit by several drugmakers that sought to change the 340B Drug Pricing Program from an upfront payment model to a backend rebate structure. Thursday's decision in U.S ...

Here we go again: An op-ed column printed in this publication is yet another example of a drug company-focused view on the 340B Drug Pricing Program, couched in the language of reform. Its criticisms ...